Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Calaspargase pegol-mknl + Cyclophosphamide + Dexamethasone + Vincristine Sulfate|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Calaspargase pegol-mknl||Asparlas||CALASP|EZN-2285EZN 2285|EZN2285|SC-PEG E. coli L-asparaginase||Asparlas (calaspargase pegol-mknl) is a pegylated version of L-asparaginase derived from E.coli, which converts L-asparagine to ammonia and L-aspartic acid, potentially resulting in reduced levels of asparagine leading to inhibition of protein synthesis and tumor cell proliferation, and increased cell death (NCI Drug Dictionary). Asparlas (calaspargase pegol-mknl) is approved as a component of multi-agent chemotherapy in acute lymphoblastic leukemia (FDA.gov).|
|Cyclophosphamide||Cytoxan||CPM||Chemotherapy - Alkylating 16||Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary).|
|Vincristine Sulfate||Oncovin||22-Oxovincaleukoblastine|vincristine||Oncovin (vincristine) binds microtubules and prevents mitotic spindle formation, resulting in cell-cycle arrest (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|